Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug‐outcome associations: The case of clindamycin and Clostridium difficile infection

The Food and Drug Administration's Sentinel System developed parameterized, reusable analytic programs for evaluation of medical product safety. Research on outpatient antibiotic exposures, and Clostridium difficile infection (CDI) with non‐user reference groups led us to expect a higher rate of CDI among outpatient clindamycin users vs penicillin users. We evaluated the ability of the Cohort Identification and Descriptive Analysis and Propensity Score Matching tools to identify a higher rate of CDI among clindamycin users.

[1]  J. Rassen,et al.  A modular, prospective, semi‐automated drug safety monitoring system for use in a distributed data environment , 2014, Pharmacoepidemiology and drug safety.

[2]  David N. Fisman,et al.  Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection , 2013, Antimicrobial Agents and Chemotherapy.

[3]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[4]  S Toh,et al.  Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association , 2016, Clinical pharmacology and therapeutics.

[5]  K. Iwata,et al.  Epidemic Clostridium difficile. , 2006, The New England journal of medicine.

[6]  Barbara Evans,et al.  A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.

[7]  E. Cook,et al.  Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort , 2006, Epidemiology and Infection.

[8]  Richard Platt,et al.  Risk of acquiring antibiotic-resistant bacteria from prior room occupants. , 2006, Archives of internal medicine.

[9]  Yan Yan,et al.  Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Dustin L. Stwalley,et al.  The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases , 2016, BMC Infectious Diseases.

[11]  G. Dumyati,et al.  Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[13]  M. Stevenson,et al.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. , 2003, The Journal of antimicrobial chemotherapy.

[14]  M. Falagas,et al.  Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[15]  K. Garey,et al.  Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.

[16]  Amanda F. Petrik,et al.  Epidemiology and Healthcare Costs of Incident Clostridium difficile Infections Identified in the Outpatient Healthcare Setting , 2012, Infection Control & Hospital Epidemiology.

[17]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Carlene A. Muto,et al.  Antimicrobial-associated risk factors for Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Suissa,et al.  Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy , 2006, Canadian Medical Association Journal.

[20]  Philip M Polgreen,et al.  Incidence of and risk factors for community-associated Clostridium difficile infection: A nested case-control study , 2011, BMC infectious diseases.

[21]  Christian Hampp,et al.  Sentinel Modular Program for Propensity Score–Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia , 2017, Epidemiology.